“…The diagnosis of CVID-ILD was confirmed by biopsy in 31 case reports and series ( 12 – 22 , 26 – 45 ) and was used as an obligatory inclusion criterium for CVID-ILD patients in eleven studies ( 5 , 24 , 25 , 54 , 56 – 60 , 62 , 63 ). Transbronchial biopsy (TBB) was described in 17 studies involving 57 patients, 28 of whom had definitive results, while the remaining patients underwent a supplemental biopsy modality to confirm the diagnosis ( 16 – 18 , 22 , 30 , 31 , 34 , 38 , 42 , 44 , 50 , 58 , 59 , 62 – 64 , 69 ). The most common diagnostic findings were non-necrotizing granulomatous and lymphocytic inflammation.…”